NCT04781972PHASE4Recruiting

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Johns Hopkins University

Start Date

7/27/2021

Completion Date

4/30/2029

Summary

The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.

Eligibility Criteria

Age Range: 6 years to 40 years

Inclusion Criteria: * right handed Exclusion Criteria: * pregnant or breast feeding * past or current neurological disorder * non-ADHD cause of cognitive impairment * uncontrolled medical disorder * head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma * having an adverse reaction to methylphenidate, or other stimulant medication * having a contraindication to MRI * current smoking

Interventions

DRUG

Methylphenidate

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

ADHD - Combined Type

Locations

Johns Hopkins School of Medicine

Baltimore, Maryland 21205

United States